FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553015816> ?p ?o ?g. }

• W2553015816 endingPage "2762" @default.
• W2553015816 startingPage "2753" @default.
• W2553015816 abstract "BackgroundMénière's disease is characterised by severe vertigo attacks and hearing loss. Intratympanic gentamicin, the standard treatment for refractory Ménière's disease, reduces vertigo, but damages vestibular function and can worsen hearing. We aimed to assess whether intratympanic administration of the corticosteroid methylprednisolone reduces vertigo compared with gentamicin.MethodsIn this double-blind comparative effectiveness trial, patients aged 18–70 years with refractory unilateral Ménière's disease were enrolled at Charing Cross Hospital (London, UK) and Leicester Royal Infirmary (Leicester, UK). Patients were randomly assigned (1:1) by a block design to two intratympanic methylprednisolone (62·5 mg/mL) or gentamicin (40 mg/mL) injections given 2 weeks apart, and were followed up for 2 years. All investigators and patients were masked to treatment allocation. The primary outcome was vertigo frequency over the final 6 months (18–24 months after injection) compared with the 6 months before the first injection. Analyses were done in the intention-to-treat population, and then per protocol. This trial is registered with ClinicalTrials.gov, number NCT00802529.FindingsBetween June 19, 2009, and April 15, 2013, 256 patients with Ménière's disease were screened, 60 of whom were enrolled and randomly assigned: 30 to gentamicin and 30 to methylprednisolone. In the intention-to-treat analysis (ie, all 60 patients), the mean number of vertigo attacks in the final 6 months compared with the 6 months before the first injection (primary outcome) decreased from 19·9 (SD 16·7) to 2·5 (5·8) in the gentamicin group (87% reduction) and from 16·4 (12·5) to 1·6 (3·4) in the methylprednisolone group (90% reduction; mean difference −0·9, 95% CI −3·4 to 1·6). Patients whose vertigo did not improve after injection (ie, non-responders) after being assessed by an unmasked clinician were eligible for additional injections given by a masked clinician (eight patients in the gentamicin group vs 15 in the methylprednisolone group). Two non-responders switched from methylprednisolone to gentamicin. Both drugs were well tolerated with no safety concerns. Six patients reported one adverse event each: three in the gentamicin group and three in the methylprednisolone group. The most common adverse event was minor ear infections, which was experienced by one patient in the gentamicin group and two in the methylprednisolone group.InterpretationMethylprednisolone injections are a non-ablative, effective treatment for refractory Ménière's disease. The choice between methylprednisolone and gentamicin should be made based on clinical knowledge and patient circumstances.FundingMénière's Society and National Institute for Health Research Imperial Biomedical Research Centre. Ménière's disease is characterised by severe vertigo attacks and hearing loss. Intratympanic gentamicin, the standard treatment for refractory Ménière's disease, reduces vertigo, but damages vestibular function and can worsen hearing. We aimed to assess whether intratympanic administration of the corticosteroid methylprednisolone reduces vertigo compared with gentamicin. In this double-blind comparative effectiveness trial, patients aged 18–70 years with refractory unilateral Ménière's disease were enrolled at Charing Cross Hospital (London, UK) and Leicester Royal Infirmary (Leicester, UK). Patients were randomly assigned (1:1) by a block design to two intratympanic methylprednisolone (62·5 mg/mL) or gentamicin (40 mg/mL) injections given 2 weeks apart, and were followed up for 2 years. All investigators and patients were masked to treatment allocation. The primary outcome was vertigo frequency over the final 6 months (18–24 months after injection) compared with the 6 months before the first injection. Analyses were done in the intention-to-treat population, and then per protocol. This trial is registered with ClinicalTrials.gov, number NCT00802529. Between June 19, 2009, and April 15, 2013, 256 patients with Ménière's disease were screened, 60 of whom were enrolled and randomly assigned: 30 to gentamicin and 30 to methylprednisolone. In the intention-to-treat analysis (ie, all 60 patients), the mean number of vertigo attacks in the final 6 months compared with the 6 months before the first injection (primary outcome) decreased from 19·9 (SD 16·7) to 2·5 (5·8) in the gentamicin group (87% reduction) and from 16·4 (12·5) to 1·6 (3·4) in the methylprednisolone group (90% reduction; mean difference −0·9, 95% CI −3·4 to 1·6). Patients whose vertigo did not improve after injection (ie, non-responders) after being assessed by an unmasked clinician were eligible for additional injections given by a masked clinician (eight patients in the gentamicin group vs 15 in the methylprednisolone group). Two non-responders switched from methylprednisolone to gentamicin. Both drugs were well tolerated with no safety concerns. Six patients reported one adverse event each: three in the gentamicin group and three in the methylprednisolone group. The most common adverse event was minor ear infections, which was experienced by one patient in the gentamicin group and two in the methylprednisolone group. Methylprednisolone injections are a non-ablative, effective treatment for refractory Ménière's disease. The choice between methylprednisolone and gentamicin should be made based on clinical knowledge and patient circumstances." @default.
• W2553015816 created "2016-11-30" @default.
• W2553015816 creator A5008231366 @default.
• W2553015816 creator A5018154482 @default.
• W2553015816 creator A5019953868 @default.
• W2553015816 creator A5029051852 @default.
• W2553015816 creator A5033582840 @default.
• W2553015816 creator A5051226613 @default.
• W2553015816 creator A5065323728 @default.
• W2553015816 creator A5068494225 @default.
• W2553015816 creator A5087124656 @default.
• W2553015816 date "2016-12-01" @default.
• W2553015816 modified "2023-10-13" @default.
• W2553015816 title "Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial" @default.
• W2553015816 cites W1578588114 @default.
• W2553015816 cites W1906222399 @default.
• W2553015816 cites W1931996274 @default.
• W2553015816 cites W1967112941 @default.
• W2553015816 cites W1974345418 @default.
• W2553015816 cites W2001165455 @default.
• W2553015816 cites W2017654697 @default.
• W2553015816 cites W2020560564 @default.
• W2553015816 cites W2022438449 @default.
• W2553015816 cites W2030624857 @default.
• W2553015816 cites W2030877917 @default.
• W2553015816 cites W2036036397 @default.
• W2553015816 cites W2053877779 @default.
• W2553015816 cites W2054488023 @default.
• W2553015816 cites W2057938285 @default.
• W2553015816 cites W2058178016 @default.
• W2553015816 cites W2059419921 @default.
• W2553015816 cites W2069863414 @default.
• W2553015816 cites W2074290823 @default.
• W2553015816 cites W2074671051 @default.
• W2553015816 cites W2079727896 @default.
• W2553015816 cites W2081453354 @default.
• W2553015816 cites W2110001084 @default.
• W2553015816 cites W2114147715 @default.
• W2553015816 cites W2120664244 @default.
• W2553015816 cites W2128069214 @default.
• W2553015816 cites W2134737863 @default.
• W2553015816 cites W2142849543 @default.
• W2553015816 cites W2149138799 @default.
• W2553015816 cites W2152440431 @default.
• W2553015816 cites W2157995946 @default.
• W2553015816 cites W2166059903 @default.
• W2553015816 cites W2197302530 @default.
• W2553015816 cites W2254890258 @default.
• W2553015816 cites W2256410958 @default.
• W2553015816 cites W2335588145 @default.
• W2553015816 cites W2368093946 @default.
• W2553015816 doi "https://doi.org/10.1016/s0140-6736(16)31461-1" @default.
• W2553015816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27865535" @default.
• W2553015816 hasPublicationYear "2016" @default.
• W2553015816 type Work @default.
• W2553015816 sameAs 2553015816 @default.
• W2553015816 citedByCount "119" @default.
• W2553015816 countsByYear W25530158162016 @default.
• W2553015816 countsByYear W25530158162017 @default.
• W2553015816 countsByYear W25530158162018 @default.
• W2553015816 countsByYear W25530158162019 @default.
• W2553015816 countsByYear W25530158162020 @default.
• W2553015816 countsByYear W25530158162021 @default.
• W2553015816 countsByYear W25530158162022 @default.
• W2553015816 countsByYear W25530158162023 @default.
• W2553015816 crossrefType "journal-article" @default.
• W2553015816 hasAuthorship W2553015816A5008231366 @default.
• W2553015816 hasAuthorship W2553015816A5018154482 @default.
• W2553015816 hasAuthorship W2553015816A5019953868 @default.
• W2553015816 hasAuthorship W2553015816A5029051852 @default.
• W2553015816 hasAuthorship W2553015816A5033582840 @default.
• W2553015816 hasAuthorship W2553015816A5051226613 @default.
• W2553015816 hasAuthorship W2553015816A5065323728 @default.
• W2553015816 hasAuthorship W2553015816A5068494225 @default.
• W2553015816 hasAuthorship W2553015816A5087124656 @default.
• W2553015816 hasBestOaLocation W25530158161 @default.
• W2553015816 hasConcept C121332964 @default.
• W2553015816 hasConcept C141071460 @default.
• W2553015816 hasConcept C142424586 @default.
• W2553015816 hasConcept C187212893 @default.
• W2553015816 hasConcept C2775832221 @default.
• W2553015816 hasConcept C2776694085 @default.
• W2553015816 hasConcept C2776804153 @default.
• W2553015816 hasConcept C2778239845 @default.
• W2553015816 hasConcept C2778534666 @default.
• W2553015816 hasConcept C2779135839 @default.
• W2553015816 hasConcept C2780372218 @default.
• W2553015816 hasConcept C2780865074 @default.
• W2553015816 hasConcept C2908647359 @default.
• W2553015816 hasConcept C42219234 @default.
• W2553015816 hasConcept C501593827 @default.
• W2553015816 hasConcept C71924100 @default.
• W2553015816 hasConcept C86803240 @default.
• W2553015816 hasConcept C87355193 @default.
• W2553015816 hasConcept C89423630 @default.
• W2553015816 hasConcept C99454951 @default.
• W2553015816 hasConceptScore W2553015816C121332964 @default.
• W2553015816 hasConceptScore W2553015816C141071460 @default.

• next